Enfermedad pulmonar intersticial asociada a rituximab. / [Rituximab-induced interstitial lung disease].
Medicina (B Aires)
; 73(4): 343-5, 2013.
Article
en Es
| BINACIS
| ID: bin-133008
ABSTRACT
The introduction of the anti-CD20 antibody rituximab into clinical practice has improved substantially the prognosis of a variety of haematological and autoimmune diseases. The interstitial lung disease is one of most serious and potentially fatal complications of rituximab therapy. This diagnosis should be considered in patients who have received the drug and present with dyspnea, fever and cough without clear evidence of infection. We report a case of rituximab-induced interstitial lung disease.
Buscar en Google
Colección:
06-national
/
AR
Base de datos:
BINACIS
Asunto principal:
Enfermedades Pulmonares Intersticiales
/
Anticuerpos Monoclonales de Origen Murino
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Idioma:
Es
Revista:
Medicina (B Aires)
Año:
2013
Tipo del documento:
Article
Pais de publicación:
Argentina